Treadwell Therapeutics, Inc.
๐บ๐ธUnited States
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Advanced Solid TumorBreast Cancer
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Treadwell Therapeutics, Inc
- Target Recruit Count
- 44
- Registration Number
- NCT05251714
- Locations
- ๐บ๐ธ
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
๐บ๐ธSTART San Antonio, San Antonio, Texas, United States
๐บ๐ธSTART - Mountain Region, West Valley City, Utah, United States
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
Phase 1
Active, not recruiting
- Conditions
- AMLMDSMyelodysplastic SyndromesCMMLAcute Myeloid LeukemiaChronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Treadwell Therapeutics, Inc
- Target Recruit Count
- 72
- Registration Number
- NCT04730258
- Locations
- ๐บ๐ธ
City of Hope, Duarte, California, United States
๐บ๐ธNorton Cancer Institute - Saint Matthews, Louisville, Kentucky, United States
๐บ๐ธNew York Presbyterian Weill Cornell Medical Center, New York, New York, United States
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
Phase 1
Active, not recruiting
- Conditions
- Advanced Solid Malignancies
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Treadwell Therapeutics, Inc
- Target Recruit Count
- 170
- Registration Number
- NCT04521413
- Locations
- ๐บ๐ธ
University of California San Diego, La Jolla, California, United States
๐บ๐ธThe Angeles Clinic, Los Angeles, California, United States
๐บ๐ธYale Cancer Center, New Haven, Connecticut, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath